ImageneBio Debuts on Nasdaq, Eyes $257B Immunology Market with Lead Asset IMG-007

Ticker: IMA · Form: S-1 · Filed: Sep 8, 2025 · CIK: 1835579

Imagenebio, INC. S-1 Filing Summary
FieldDetail
CompanyImagenebio, INC. (IMA)
Form TypeS-1
Filed DateSep 8, 2025
Risk Levelhigh
Pages15
Reading Time18 min
Key Dollar Amounts$0.001, $7.96, $29.90, $75.0 million, $103 billion
Sentimentmixed

Sentiment: mixed

Topics: Biotechnology, Clinical Stage, Autoimmune Diseases, Immunology, Atopic Dermatitis, S-1 Filing, PIPE Financing

Related Tickers: IMA, ABBV, LLY, AMGN

TL;DR

**ImageneBio's post-merger debut with a $75M PIPE and promising early clinical data for IMG-007 makes it a speculative buy in the hot I&I market, but significant funding needs and a material weakness are red flags.**

AI Summary

ImageneBio, Inc. (IMA) is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune, immunological, and inflammatory (I&I) indications. The company's lead asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody initially targeting atopic dermatitis (AD), with potential for other I&I diseases like alopecia areata, asthma, and COPD. A Phase 1b/2a clinical trial for IMG-007 in AD showed 54% of patients achieved EASI-75 at Week 20 after three treatments, with no serious adverse events, pyrexia, or chills. The global immunology market is projected to grow from approximately $103 billion in 2024 to $257 billion by 2032, indicating significant market potential. ImageneBio was formed on July 25, 2025, through a merger between Ikena Oncology, Inc. and Legacy Inmagene, which included a 1-for-12 reverse stock split of Ikena's common stock. Concurrently, a PIPE financing raised approximately $75.0 million through the sale of 2,508,337 shares at approximately $29.90 per share. The company's common stock began trading on Nasdaq under the symbol "IMA" on July 28, 2025. ImageneBio is an "emerging growth company" and a "smaller reporting company." The company relies on an exclusive license from Hutchmed for IMG-007 technology and Wuxi Biologics for manufacturing. ImageneBio expects to incur significant losses and will require substantial additional funding for development and commercialization. Legacy Inmagene identified a material weakness in its internal controls.

Why It Matters

This S-1 filing marks ImageneBio's public debut on Nasdaq under the symbol 'IMA' following its merger and a $75.0 million PIPE financing, providing crucial capital for its clinical-stage pipeline. For investors, the success of IMG-007, a non-depleting anti-OX40 monoclonal antibody, in the rapidly growing $257 billion global immunology market is paramount, especially given its promising Phase 1b/2a AD trial results. Employees and customers could benefit from a new, potentially differentiated therapy for chronic I&I diseases, but the company faces intense competition from established players like Humira and Skyrizi, which have multi-indication approvals. The identified material weakness in Legacy Inmagene's internal controls also warrants investor scrutiny.

Risk Assessment

Risk Level: high — ImageneBio is a clinical-stage biopharmaceutical company with a limited operating history and expects to incur significant losses for the foreseeable future. The company's business is entirely dependent on the success of IMG-007, and it will need to obtain substantial additional funding beyond the $75.0 million PIPE financing to complete development and commercialization, which may cause dilution to stockholders. Furthermore, Legacy Inmagene identified a material weakness in its internal controls, indicating potential financial reporting risks.

Analyst Insight

Investors should approach ImageneBio with caution, recognizing its high-risk profile as a clinical-stage company. While the early Phase 1b/2a data for IMG-007 is promising and the I&I market is large, the company's significant future funding requirements and the identified material weakness in internal controls demand careful consideration. Monitor the progress of IMG-007's Phase 2b study and future financing rounds closely before making a substantial investment.

Financial Highlights

debt To Equity
N/A
revenue
$0
operating Margin
N/A
total Assets
N/A
total Debt
N/A
net Income
N/A
eps
N/A
gross Margin
N/A
cash Position
$75.0 million
revenue Growth
N/A

Key Numbers

Key Players & Entities

FAQ

What is ImageneBio's lead product candidate and what diseases does it target?

ImageneBio's lead product candidate is IMG-007, a non-depleting anti-OX40 monoclonal antibody. It is initially being developed for atopic dermatitis (AD) but has potential for other autoimmune, immunological, and inflammatory (I&I) indications such as alopecia areata, asthma, and chronic obstructive pulmonary disease (COPD).

How much capital did ImageneBio raise in its recent PIPE financing?

ImageneBio raised aggregate gross proceeds of approximately $75.0 million through a PIPE (Private Investment in Public Equity) financing. This involved the sale of 2,508,337 shares of common stock at a price of approximately $29.90 per share on July 25, 2025.

What were the key results from IMG-007's Phase 1b/2a clinical trial for atopic dermatitis?

In the Phase 1b/2a AD study, 54% of patients achieved EASI-75 (75% reduction in eczema area and severity index) at Week 20 after only three treatments. The study also reported no serious adverse events, pyrexia, or chills among the 13 treated patients, indicating a favorable safety profile.

What is the projected growth of the global immunology market?

The global immunology market is expected to grow significantly, from approximately $103 billion in 2024 to an estimated $257 billion by 2032. This substantial growth highlights the increasing demand and market opportunity for therapies in autoimmune and inflammatory diseases.

What is the corporate structure of ImageneBio, Inc. following the merger?

ImageneBio, Inc. was formed on July 25, 2025, through a merger where Ikena Oncology, Inc. merged with Legacy Inmagene. Prior to the merger, Ikena effected a 1-for-12 reverse stock split. Following the merger, Ikena Oncology, Inc. changed its name to ImageneBio, Inc., and its common stock began trading on Nasdaq under the symbol "IMA" on July 28, 2025.

What are the primary risks associated with investing in ImageneBio?

Key risks include ImageneBio's status as a clinical-stage company with a limited operating history and expected significant losses. The company's success is entirely dependent on IMG-007, and it will require substantial additional funding, which could dilute stockholders. Furthermore, Legacy Inmagene identified a material weakness in its internal controls, posing financial reporting risks.

Who are the key partners for ImageneBio regarding IMG-007?

ImageneBio has an exclusive license for IMG-007 and its underlying technology from Hutchmed. Additionally, the company relies on Wuxi Biologics to supply the active pharmaceutical ingredients and manufacture the drug product for IMG-007.

What is the significance of OX40 in I&I diseases?

OX40 is a cell-surface receptor protein primarily expressed by activated T cells, which are central to many autoimmune diseases. The interaction between OX40 and its ligand (OX40L) stimulates T cell proliferation and the release of pro-inflammatory cytokines, contributing to inflammation. Inhibiting this pathway, as IMG-007 aims to do, could be a therapeutic strategy across a wide range of I&I diseases.

Is ImageneBio considered an emerging growth company or a smaller reporting company?

Yes, ImageneBio, Inc. is classified as both an "emerging growth company" and a "smaller reporting company" under federal securities laws. This classification allows the company to comply with certain reduced public company reporting requirements for future filings.

What is the current trading symbol and exchange for ImageneBio's common stock?

ImageneBio's common stock is listed on The Nasdaq Capital Market under the symbol "IMA." Trading commenced on July 28, 2025, following the completion of the merger and name change.

Risk Factors

Industry Context

ImageneBio operates in the rapidly expanding global immunology market, projected to grow from $103 billion in 2024 to $257 billion by 2032. This market is characterized by significant unmet needs in autoimmune, immunological, and inflammatory diseases. The competitive landscape includes both large pharmaceutical companies and numerous biotechnology firms, all vying for market share with novel therapeutic approaches.

Regulatory Implications

As a clinical-stage biopharmaceutical company, ImageneBio faces significant regulatory hurdles. The success of IMG-007 hinges on successful completion of clinical trials demonstrating safety and efficacy to gain FDA approval. Any delays, adverse findings, or changes in regulatory pathways could materially impact the company's development timeline and commercial viability.

What Investors Should Do

  1. Monitor clinical trial progress and data readouts for IMG-007.
  2. Assess the company's ability to secure future funding rounds.
  3. Evaluate the management team's experience in navigating regulatory and commercialization challenges.

Key Dates

Glossary

EASI-75
Eczema Area and Severity Index score reduction of 75%. It is a common measure of treatment efficacy in atopic dermatitis. (Key clinical endpoint demonstrating the effectiveness of IMG-007 in the Phase 1b/2a trial.)
Non-depleting anti-OX40 monoclonal antibody
A type of antibody therapy that targets the OX40 receptor on immune cells without depleting (reducing the number of) these cells. This approach aims to modulate immune responses rather than suppress them. (Describes the mechanism of action for ImageneBio's lead asset, IMG-007, and its potential therapeutic approach.)
PIPE Financing
Private Investment in Public Equity. A type of financing where institutional investors purchase securities directly from a publicly traded company. (The $75.0 million raised through PIPE financing is crucial for funding ImageneBio's operations and development.)
Reverse Stock Split
A corporate action where a company reduces the number of outstanding shares by consolidating existing shares into fewer, proportionally more valuable shares. (Ikena Oncology, Inc. executed a 1-for-12 reverse stock split prior to the merger, impacting the share structure.)
Emerging Growth Company
A designation under the JOBS Act that allows certain companies to benefit from reduced reporting requirements and other regulatory accommodations. (ImageneBio qualifies as an EGC, which may affect its disclosure obligations and compliance costs.)
Smaller Reporting Company
A company that meets certain thresholds for public float and revenue, allowing for scaled-down financial reporting requirements. (ImageneBio's status as an SRC also impacts its disclosure obligations.)

Year-Over-Year Comparison

As this is a newly formed entity through a merger and its initial S-1 filing, there is no prior year's filing to compare against. Key financial metrics such as revenue, net income, and margins are not yet established for ImageneBio, Inc. The primary financial event discussed is the $75.0 million PIPE financing. New risks related to the combined entity's operations, reliance on key partners, and the identified material weakness in internal controls are now relevant.

Filing Stats: 4,554 words · 18 min read · ~15 pages · Grade level 17.6 · Accepted 2025-09-08 16:18:04

Key Financial Figures

Filing Documents

RISK FACTORS

RISK FACTORS 6 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 70

USE OF PROCEEDS

USE OF PROCEEDS 72 MARKET PRICE OF AND DIVIDENDS ON THE REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS 73 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION 74 IMAGENEBIO, INC.'S MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 93 INMAGENE BIOPHARMACEUTICALS' MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 106

BUSINESS

BUSINESS 117 MANAGEMENT 160

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 167 CERTAIN RELATIONSHIPS, RELATED PARTY AND OTHER TRANSACTIONS 191 PRINCIPAL SECURITYHOLDERS 197 SELLING STOCKHOLDERS 200

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 204 PLAN OF DISTRIBUTION 206 LEGAL MATTERS 208 EXPERTS 208 WHERE YOU CAN FIND ADDITIONAL INFORMATION 208 i Table of Contents EXPLANATORY NOTE On July 25, 2025 (the "Closing Date"), ImageneBio, Inc., a Delaware corporation (previously named Ikena Oncology, Inc.), a Delaware corporation, consummated the previously announced merger pursuant to the terms of the Agreement and Plan of Merger, dated as of December 23, 2024 (the "Merger Agreement"), by and among Ikena Oncology, Inc. ("Ikena"), Insight Merger Sub I, an exempted company with limited liability incorporated and existing under the laws of the Cayman Islands and a direct, wholly owned subsidiary of Ikena ("Merger Sub I"), Insight Merger Sub II, an exempted company with limited liability incorporated and existing under the laws of the Cayman Islands and a direct, wholly owned subsidiary of Ikena ("Merger Sub II"), and Inmagene Biopharmaceuticals, an exempted company with limited liability incorporated and existing under the laws of the Cayman Islands ("Legacy Inmagene"). Unless otherwise stated or the context otherwise requires, the references in this prospectus to the "Company," "we," "our," or "us" refer to Inmagene Biopharmaceuticals together with its consolidated subsidiaries for periods prior to the Merger and to ImageneBio, Inc. together with its consolidated subsidiaries for periods following the Merger; references to "Ikena" refer to Ikena Oncology, Inc. for periods prior to the Merger; and references to "Legacy Inmagene" refer to Inmagene Biopharmaceuticals together with its consolidated subsidiaries for periods prior to the Merger. Pursuant to the Merger Agreement, on the Closing Date, (i) Ikena effected a 1-for-12 reverse stock split of Ikena's issued common stock (the "Reverse Stock Split"), (ii) Merger Sub I merged with and into Legacy Inmagene (the "First Merger"), with Legacy Inmagene surviving the First Merger as a wholly owned subsidiary of

Use of Proceeds

Use of Proceeds We will not receive any proceeds from the sale of our shares of common stock offered by the selling stockholders under this prospectus. See the section titled "Use of Proceeds" appearing elsewhere in this prospectus for more information.

Risk Factors

Risk Factors See the section titled "Risk Factors" and other information included in this prospectus for a discussion of factors that you should consider carefully before deciding to invest in our common stock. Nasdaq Symbol "IMA" 5 Table of Contents

RISK FACTORS

RISK FACTORS An investment in our common stock involves a high degree of risk. In addition to the risk and uncertainties described under the section titled "Cautionary Note

View Full Filing

View this S-1 filing on SEC EDGAR

View on Read The Filing